Evidence map›Paper›PMID 41064134›Full record

ArticleRSC advances2025

Novel prolyl endopeptidase inhibitor from

Khair Ullah, Tasneef Azam, Abdul Sammad, Tanveer Ahmed, Abdul Wadood, Muhammad Fawad Ali, Ghulam M Mushraf, Bina Shaheen Siddiqui, Yin-Xiong Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. GenusLife (Basel, Switzerland) · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Khair UllahCenter for Cell Lineage Technology and Engineering, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Guangzhou 510530 China li_yinxiong_iph@gibh.ac.cn.
Tasneef AzamH.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi Karachi 75270 Pakistan siddiqui_bina@yahoo.com.
Abdul SammadCenter for Cell Lineage Technology and Engineering, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Guangzhou 510530 China li_yinxiong_iph@gibh.ac.cn.
Tanveer AhmedCenter for Cell Lineage Technology and Engineering, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Guangzhou 510530 China li_yinxiong_iph@gibh.ac.cn.
Abdul WadoodDepartment of Biochemistry, Abdul Wali Khan University Mardan Mardan-23200 Pakistan.ORCID https://orcid.org/0000-0002-3415-9277
Muhammad Fawad AliDepartment of Biochemistry, Abdul Wali Khan University Mardan Mardan-23200 Pakistan.
Ghulam M MushrafCenter for Cell Lineage Technology and Engineering, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Guangzhou 510530 China li_yinxiong_iph@gibh.ac.cn.
Bina Shaheen SiddiquiH.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi Karachi 75270 Pakistan siddiqui_bina@yahoo.com.ORCID https://orcid.org/0000-0001-8160-0021
Yin-Xiong LiCenter for Cell Lineage Technology and Engineering, Guangdong Provincial Key Laboratory of Biocomputing, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences Guangzhou 510530 China li_yinxiong_iph@gibh.ac.cn.ORCID https://orcid.org/0000-0001-8331-9903

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prolyl endopeptidase (PREP), a serine protease, plays a critical role in the progression of hepatic steatosis and thereby contributes to metabolic dysfunction-associated fatty liver disease (MAFLD). Its inhibition has been shown to reverse disease progression. This study aimed to identify effective PREP inhibitors derived from

Identifiers

PMID41064134
PMCPMC12501607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.